BioSpace News Archive

Global Cerebral Palsy Treatment Market Size to Reach USD 2.23 billion in 2025 | Emergen Research

The global cerebral palsy treatment market size is expected to reach USD 2.23 billion by 2025, according to laetst study by Emergen Research, expanding at a CAGR of 7.0% during the forecast period.

September 16, 2022
·
6 min read
Policy

FDA Review: Abiomed, Mallinckrodt, Aro and More

The FDA has a broad range of activities in the drug and medical device space. Here’s a look at the agency’s work this week.

September 16, 2022
·
3 min read
·
Mark Terry
FDA

Merck Capitalizes on Keytruda’s Combination Potential

With 33 approvals from the FDA, Merck’s checkpoint inhibitor Keytruda has become a powerhouse oncology drug and is likely to continue to rack up more regulatory wins.

September 16, 2022
·
4 min read
·
Alex Keown
5 Lupus Patients in Remission Following CAR T Cell Therapy

Five patients with systemic lupus erythematosus (SLE) are in remission after receiving CAR T cell therapy, according to a recent study.

September 16, 2022
·
2 min read
·
Tristan Manalac
Drug Development

AstraZeneca’s Complementary PNH Treatment Hits the Mark in Phase III

AstraZeneca’s rare disease subsidiary Alexion posted positive late-stage results from a potential complementary treatment for paroxysmal nocturnal hemoglobinuria.

September 16, 2022
·
3 min read
·
Alex Keown
Research Roundup: Brain Inflammation in Monkeypox, Repurposing Drugs for Autism & More

Neuronal Inflammation was found in two U.S. monkeypox patients, researchers short-list four drugs for potential study in autism and a new test can predict immunotherapy outcomes.

September 16, 2022
·
4 min read
·
Katherine Davis
Drug Development

Mallinckrodt’s Terlivaz Becomes First FDA-Approved Drug for Hepatorenal Syndrome

The U.S. FDA approved Mallinckrodt’s Terlivaz in adults with hepatorenal syndrome and is the only FDA-approved drug for that indication.

September 16, 2022
·
3 min read
·
Mark Terry
Career Advice

What You Need to Know to Become a Biochemist

Becoming a chemist in the biopharma industry takes hard work, dedication and a willingness to continuously learn. Here’s what you need to know to become a biochemist.

September 16, 2022
·
5 min read
·
Franklin Carpenter
Drug Development

Intellia’s Latest Data Indicate Full Potential of CRISPR

Intellia Therapeutics reported early, positive signs from its in vivo gene therapies for both transthyretin (ATTR) amyloidosis and hereditary angioedema Friday.

September 16, 2022
·
3 min read
·
Alex Keown
Policy

WHO denounces GSK-VIR, Regeneron COVID drugs following Lancet Criticism

The Lancet Commission published a lengthy criticism of the WHO’s COVID-19 pandemic response. In turn, the WHO offered a reply to a number of the complaints.

September 16, 2022
·
5 min read
·
Mark Terry